Delcath Systems Inc. (DCTH) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Delcath Systems Inc. (NASDAQ: DCTH) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $14.64 (-1.48% 1D, market cap $508.0M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, DCTH ranks #255 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), DCTH carries a Roarable D+ (57/100 RQD), trailing P/E of N/A, gross margin of 86.2%, and ROIC of 0.8%. By comparison, SENS (Senseonics Holdings Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $515.5M) and RCEL (Avita Medical Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $516.8M). Among the 5-stock peer group, DCTH leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).
Per DCTH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000872912), Delcath Systems Inc. generated $85.2M in revenue (+129.1% YoY), $2.7M in net income, and $21.0M in free cash flow against $123.6M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 20.33 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9
SEC XBRL FY 2025 (10-K): 24.6% FCF Margin ($21.0M FCF) & 86.2% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)
Even with a 57/100 (D+) score, DCTH faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
Dilution & Margin Drag: Cannibal Buyback (-0.96% YoY Shares) — any gross margin slip below 83.7% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($15.66) or 200D SMA ($12.34) invalidates the momentum regime and cuts Target Base ($14.57) toward Bear Floor ($11.36).
Delcath Systems Inc. (DCTH) slipped -1.48% to $14.64, trading at 70% of its 52-week range ($8.12 – $17.42). Stretched risk/reward at current multiples (1% return on capital) under elevated 10-year interest-rate pressure.
QUEENSBURY, N.Y., October 27, 2026--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will b
QUEENSBURY, N.Y., October 26, 2026--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a confere
QUEENSBURY, N.Y., October 19, 2026--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced presentations related
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced presentations related to its clinical development
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +129.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on DCTH today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for DCTH. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Delcath Systems Inc. (DCTH) ranks #255 by composite RQD confidence (57/100, grade D+) and #447 by equity capitalization ($508.0M). Within this direct 5-issuer industry benchmark cohort, DCTH leads on earnings valuation at N/A trailing P/E, while DCTH leads on capital efficiency and profitability with 0.8% ROIC and 86.2% gross margin. DCTH currently leads its immediate peer cohort in composite quantitative strength at 57/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| DCTH
ACTIVE
Delcath Systems Inc. | D+ | 57/100 | — | 86.2% | 0.8% | -1.48% | $508.0M | Benchmark Subject |
| SENS Senseonics Holdings Inc. | D- | 38/100 | — | 44.7% | -35.0% | +4.39% | $515.5M | /sens-vs-dcth → |
| RCEL Avita Medical Inc. | D | 44/100 | — | 82.1% | -35.0% | +1.27% | $516.8M | /rcel-vs-dcth → |
| ANGO AngioDynamics Inc. | D | 50/100 | — | 54.6% | -23.4% | +1.81% | $519.4M | /ango-vs-dcth → |
| CERS Cerus Corporation | D- | 37/100 | — | — | -15.5% | +0.83% | $491.7M | /cers-vs-dcth → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Delcath Systems Inc. (DCTH) reported GAAP revenue of $85.2M (+129.1% vs. FY2024 revenue of $37.2M , and +4027.4% cumulative change since FY2023) , GAAP net income of $2.7M, operating cash flow of $22.5M, and free cash flow of $21.0M (+209.0% YoY). On the balance sheet, DCTH closed FY2025 with $123.6M in total assets against $0 in total debt (Altman Z-Score: 20.33, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $85.2M | $2.7M | $22.5M | $21.0M | $123.6M | — |
| FY2024 (FY) | 2024-12-31 | $37.2M | -$26.4M | -$18.7M | -$19.2M | $76.6M | — |
| FY2023 (FY) | 2023-12-31 | $2.1M | -$47.7M | -$31.3M | -$31.3M | — | — |
As of 2026-11-01, Delcath Systems Inc. (NASDAQ: DCTH) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $14.64 (-1.48% 1D, market cap $508.0M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, DCTH ranks #255 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), DCTH carries a Roarable D+ (57/100 RQD), trailing P/E of N/A, gross margin of 86.2%, and ROIC of 0.8%. By comparison, SENS (Senseonics Holdings Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $515.5M) and RCEL (Avita Medical Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $516.8M). Among the 5-stock peer group, DCTH leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).
Per DCTH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000872912), Delcath Systems Inc. generated $85.2M in revenue (+129.1% YoY), $2.7M in net income, and $21.0M in free cash flow against $123.6M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
DCTH last traded at $14.64 (-1.48% on volume of 239,261 shares), positioning the stock -6.51% below its 50-day simple moving average ($15.66) and +18.64% above its 200-day simple moving average ($12.34). Across its 52-week range of $8.12 to $17.42, DCTH sits at the 70.1% percentile with a 14-day RSI of 37.3 (NEUTRAL RANGE) and an implied next-earnings move of ±8.2% ($13.44 to $15.84).
Why DCTH Stock slipped -1.48% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (1% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.